Company intelligence / Profile preview

AngioBiomed

Hennigsdorf, Brandenburg, Germany

Ownership: Private
Development stage: Other

Overview

AngioBiomed GmbH is a German biotechnology company based in Hennigsdorf and a wholly-owned subsidiary of Deutsche Biotech Innovativ AG (DBI AG). Founded in 2015, the company specializes in developing antibody-based therapies for cancer, with a focus on inhibiting tumor-induced angiogenesis. Its lead program, AB2302, is a monoclonal antibody designed to neutralize adrenomedullin (ADM), a peptide hormone that promotes the growth of blood vessels that supply tumors. By blocking ADM, AB2302 aims to starve tumors of oxygen and nutrients, serving as a complementary treatment to standard cancer therapies. The candidate is currently in preclinical development and has demonstrated efficacy in reducing tumor progression in animal models.

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on AngioBiomed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AngioBiomed.

Explore the full profile